HD-OPM Archive
Hashtags

#metformin

62 posts

Six non-diabetes benefits of metformin shown in trials, and the TAME aging hypothesis

Aug 24, 2024 · Louis Nervegna ♥ 20 · 💬 29 Aging & longevity

The post lists six effects of metformin reported in randomized trials of non-diabetics (long Covid, Covid outcomes, periodontal disease, muscle loss, knee osteoarthritis pain, oral pre-cancer lesions) and argues they share aging as a risk factor. It mentions a monkey study and the planned TAME trial testing whether metformin slows aging; most evidence is linked via Facebook shares.

Mild mitochondrial stress from statins is hormetic, not harmful

Nov 17, 2025 · Louis Nervegna ♥ 25 · 💬 11 Statins

Louis argues that mild mitochondrial toxicity from statins, metformin, exercise and calorie restriction is mitohormesis, which is beneficial at low doses. He says influencer claims that statins damage mitochondria misrepresent this.

Statins activate AMPK via mild mitochondrial stress, which Louis argues is beneficial

Nov 23, 2023 · Louis Nervegna ♥ 19 · 💬 12 ↩ 5 Statins

Louis argues statins do not harmfully impair mitochondria; instead, like metformin, they mildly stress mitochondria and activate the longevity-linked AMPK pathway (mitohormesis), possibly contributing to cardiovascular benefit. He cites a 2006 Circulation study showing statins activate AMPK in vitro and in vivo, leading to endothelial NO synthase activation. The extension to lifespan and mitohormesis is his interpretation.

Statins activate AMPK, the same longevity pathway as metformin

Nov 11, 2025 · Louis Nervegna ♥ 20 · 💬 11 ↩ 1 Statins

Louis argues that statins do not harmfully impair mitochondria; the mild stress they cause is hormetic and activates AMPK, much like metformin, which may help explain statins' benefits beyond LDL lowering. He cites a Circulation paper showing statins activate AMPK in vitro and in vivo, leading to endothelial NO synthase activation.

Metformin slowed brain aging in monkeys, with neurons resembling those 6 years younger

Sep 12, 2024 · Louis Nervegna ♥ 15 · 💬 11 ↩ 6 Aging & longevity

Louis flags a Cell study, covered by Nature, in which male monkeys on daily metformin for over three years showed slower age-related brain decline, enhanced cognition and preserved liver function. Their neuronal activity resembled monkeys about six years younger (around 18 human years). The study was small, and human benefit is unproven.

Statin muscle pain is common in some, severe damage is rare; statins may aid sarcopenia

Jan 02, 2025 · Louis Nervegna ♥ 7 · 💬 15 Statins

Louis argues statins are not toxic to muscle in most people. Myalgia occurs in some, possibly with a genetic susceptibility, while rhabdomyolysis is very rare (about 1 in 100,000, or 1 in 10,000 conservatively). Switching statins (e.g., to pravastatin or pitavastatin) or using non-statin LDL drugs can help, and low-dose statins are being studied as a treatment for sarcopenia.

Metformin is being tested for CVD, cancer and Alzheimer's, but mechanisms are unclear

Mar 08, 2024 · Louis Nervegna ♥ 14 · 💬 8 Insulin resistance & diabetes

Louis shares a Medscape article on renewed academic interest in metformin for conditions beyond diabetes, including cardiovascular, neurodegenerative, liver, kidney disease and cancers. Many new trials are underway, and it is unclear whether benefits come from glucose lowering and insulin sensitizing or other actions like mTOR inhibition. This is emerging, not established, evidence.

Statins create mild mitochondrial stress that triggers protective mitohormesis

Nov 11, 2025 · Louis Nervegna ♥ 13 · 💬 7 ↩ 2 Statins

Louis explains that mild mitochondrial toxicity is not necessarily harmful and can be beneficial through mitohormesis, the mechanism he links to metformin, statins, exercise and calorie restriction. He cites a review proposing mitohormesis as another pleiotropic effect of statins and stresses that dose matters.

One zoledronate infusion cut vertebral fractures about 44% over 10 years in women 50-60

Jan 18, 2025 · Gokhan Can ♥ 4 · 💬 9 Hormones, women's & men's health

Gokhan shares the NEJM 10-year randomized trial of infrequent zoledronate in early postmenopausal women (50-60 years) with normal-to-low-normal bone density. Zoledronate roughly halved new morphometric vertebral fractures versus placebo, and he calls it a longevity-type drug like statins or aspirin. The trial concerns bone rather than heart outcomes.

Metformin may work partly by reshaping the gut microbiome

Nov 28, 2025 · Louis Nervegna ♥ 13 · 💬 1 Gut microbiome

A shared post says studies show metformin increases helpful gut species such as Akkermansia and Bacteroides that improve glucose control. Findings are mostly in animals and organoids; no bacteria have replaced metformin in large human trials.

Metformin mildly raises lactate, which Louis argues is beneficial; lactate fuels the brain

Mar 25, 2025 · Louis Nervegna ♥ 11 · 💬 1 Insulin resistance & diabetes

Louis notes that metformin mildly raises lactate and that claims this is harmful are wrong, sharing a FoundMyFitness post on lactate as brain fuel. That post says intense exercise above 85% of max heart rate generates lactate, which the brain uses and which boosts BDNF, citing research that six minutes of high-intensity cycling raised BDNF 4-5x. No primary study is named for the metformin claim.

GLP-1 drugs vs metformin in obese prediabetes: 31% less diabetes, 41% lower mortality

Nov 06, 2026 · Louis Nervegna ♥ 7 GLP-1 drugs (semaglutide, tirzepatide)

Louis shares a large observational AHA 2026 study of 256,492 adults with prediabetes and obesity: GLP-1 users had 31% lower risk of type 2 diabetes and 41% lower mortality than metformin users. They also had fewer strokes, heart attacks and heart failure cases. The data are unpublished, observational and not yet peer reviewed, and Louis ties the results to ectopic fat and calorie restriction.